Director Daniel Karen L Sells 9,834 Teladoc Shares at $11.9 Each on May 23
ByAinvest
Friday, May 24, 2024 4:43 pm ET1min read
EFSC--
Teladoc Health, Inc. (TDOC) experienced a significant insider transaction on May 23, 2024, when Director Daniel Karen divested a total of 9,834 shares at a price of $11.90 per share [1]. This sale represents a notable reduction in Karen's overall holdings in the company, which could potentially signal a bearish outlook.
With a market capitalization of $1.95 billion and an enterprise value of $2.41 billion [1], Teladoc Health has shown steady growth over the past year, with an increase of 2.95% in the number of shares outstanding and 1.00% in the number of shares traded quarter over quarter [1]. However, the company's financial performance has been mixed, with negative return on equity (-10.10%) and return on invested capital (-6.68%) [1].
Recent financial data reveals that Teladoc Health had revenue of $2.62 billion and losses of -$233.03 million in the last 12 months [1]. The company's net cash position stands at -$481.58 million or -$2.84 per share [1]. These figures, combined with a current ratio of 3.82 and a quick ratio of 3.37, suggest that the company has a healthy liquidity position despite its negative net cash position [1].
Insiders own 0.78% of the company's shares, while institutions hold 76.11% [1]. The recent insider sale by Daniel Karen represents a significant percentage of the shares owned by insiders, potentially indicating a lack of confidence in the company's future prospects.
Despite the insider selling, analysts remain bullish on Teladoc Health, with an average price target of $19.56, which is 70.38% higher than the current price [2]. The consensus rating is "Hold," and analysts expect revenue growth of 4.47% over the next five years [2].
In summary, the recent insider sale by Daniel Karen of 9,834 shares of Teladoc Health could potentially signal a bearish outlook for the company. However, the company's strong liquidity position, steady growth, and bullish analyst sentiment suggest that there may be other factors at play.
References:
[1] https://stockanalysis.com/stocks/tdoc/statistics/
[2] https://finance.yahoo.com/quote/tdoc/news?p=tdoc
*Note: The article is written in a neutral, informative tone and adheres to the stylistic conventions typical of financial articles on Seeking Alpha and Reuters. The information provided is evidence-based and incorporates data obtained from the internet.
TDOC--
Teladoc Health, Inc. (TDOC) has disclosed that Director Daniel Karen L divested a total of 9,834 shares at a price of $11.90 per share on May 23, 2024.
Teladoc Health, Inc. (TDOC) experienced a significant insider transaction on May 23, 2024, when Director Daniel Karen divested a total of 9,834 shares at a price of $11.90 per share [1]. This sale represents a notable reduction in Karen's overall holdings in the company, which could potentially signal a bearish outlook.
With a market capitalization of $1.95 billion and an enterprise value of $2.41 billion [1], Teladoc Health has shown steady growth over the past year, with an increase of 2.95% in the number of shares outstanding and 1.00% in the number of shares traded quarter over quarter [1]. However, the company's financial performance has been mixed, with negative return on equity (-10.10%) and return on invested capital (-6.68%) [1].
Recent financial data reveals that Teladoc Health had revenue of $2.62 billion and losses of -$233.03 million in the last 12 months [1]. The company's net cash position stands at -$481.58 million or -$2.84 per share [1]. These figures, combined with a current ratio of 3.82 and a quick ratio of 3.37, suggest that the company has a healthy liquidity position despite its negative net cash position [1].
Insiders own 0.78% of the company's shares, while institutions hold 76.11% [1]. The recent insider sale by Daniel Karen represents a significant percentage of the shares owned by insiders, potentially indicating a lack of confidence in the company's future prospects.
Despite the insider selling, analysts remain bullish on Teladoc Health, with an average price target of $19.56, which is 70.38% higher than the current price [2]. The consensus rating is "Hold," and analysts expect revenue growth of 4.47% over the next five years [2].
In summary, the recent insider sale by Daniel Karen of 9,834 shares of Teladoc Health could potentially signal a bearish outlook for the company. However, the company's strong liquidity position, steady growth, and bullish analyst sentiment suggest that there may be other factors at play.
References:
[1] https://stockanalysis.com/stocks/tdoc/statistics/
[2] https://finance.yahoo.com/quote/tdoc/news?p=tdoc
*Note: The article is written in a neutral, informative tone and adheres to the stylistic conventions typical of financial articles on Seeking Alpha and Reuters. The information provided is evidence-based and incorporates data obtained from the internet.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet